Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143286 · ClinicalTrials.gov registry record · Phase 3
A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation
A Phase 3 study of Smoking Cessation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
- 20
- Study locations
NCT00143286: Completed Phase 3 study of Smoking Cessation, sponsored by Pfizer.
NCT00143286 is a Phase 3 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 2,000 participants, above the 464-participant average among 188 other Smoking Cessation trials with a reported enrollment target (331% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00143286, a Phase 3 study of Smoking Cessation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.
Conditions Studied
Interventions
- DRUG varenicline (CP-526,555)
Study Locations (20)
Other
- Pfizer Investigational Site - Prague
- Pfizer Investigational Site - Aarhus C
- Pfizer Investigational Site - Frederikssund
- Pfizer Investigational Site - Bergen
- Pfizer Investigational Site - Hønefoss
- Pfizer Investigational Site - Oslo
- Pfizer Investigational Site - Gothenburg
Ontario
- Pfizer Investigational Site - Ottawa
- Pfizer Investigational Site - Toronto
California
- Pfizer Investigational Site - Santa Ana
Florida
- Pfizer Investigational Site - West Palm Beach
Kentucky
- Pfizer Investigational Site - Lexington
Ohio
- Pfizer Investigational Site - Mogadore
Texas
- Pfizer Investigational Site - Dallas
Washington
- Pfizer Investigational Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
What the finished NCT00143286 record still lists
NCT00143286 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 464-participant average among 188 other Smoking Cessation trials with a reported enrollment target (331% higher).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which varenicline (CP-526,555) is the first listed.
NCT00143286 names 20 study sites across 13 states, led by Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT00143286 about?
NCT00143286 is a clinical study titled "A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation". The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.
What is the current status of trial NCT00143286?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2003-04. Estimated completion is 2005-03.
What conditions does trial NCT00143286 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00143286?
The interventions under investigation include: varenicline (CP-526,555) (DRUG).
Who is sponsoring clinical trial NCT00143286?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00143286 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00143286's enrollment target sits among peer trials
2,000 7th of 188 higher than 181 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia